Intranasal insulin therapy for cognitive impairment and neurodegeneration: Current state of the art

Expert Opinion on Drug Delivery

Volumn 10, Issue 12, 2013, Pages 1699-1709

  De La Monte, Suzanne M ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Diabetes mellitus; Insulin resistance; Insulin sensitizers; Insulin like growth factor; Intranasal insulin; Mild cognitive impairment; Obesity; Peroxisome proliferator activated receptor agonists

Indexed keywords

INSULIN; INSULIN RECEPTOR; MYELIN; ROSIGLITAZONE; SOMATOMEDIN C; ANTIDIABETIC AGENT;

ALZHEIMER DISEASE; CELL SURVIVAL; COGNITION; COGNITIVE DEFECT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG TRANSPORT; ELEVATED BLOOD PRESSURE; ENERGY METABOLISM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INSULIN RESISTANCE; INSULIN TREATMENT; MEAN ARTERIAL PRESSURE; MEDICAL LITERATURE; MEMORY; MIDDLE CEREBRAL ARTERY OCCLUSION; MILD COGNITIVE IMPAIRMENT; NERVE CELL PLASTICITY; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE MUCOSA; OBESITY; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BRAIN; COGNITION DISORDERS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NEURODEGENERATIVE DISEASES; PHYSIOLOGY;

ADMINISTRATION, INTRANASAL; ANIMALS; BRAIN; COGNITION DISORDERS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; NEURODEGENERATIVE DISEASES;

EID: 84889001107     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.856877     Document Type: Review

References (117)

1. Hallschmid M, Schultes B. Central nervous insulin resistance: a promising target in the treatment of metabolic and cognitive disorders? Diabetologia 2009;52:2264-9
2. Rivera EJ, Goldin A, Fulmer N, et al. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimer's Dis 2005;8:247-68
3. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimer's Dis 2005;7:63-80 (Pubitemid 40387185)
4. de la Monte SM. Insulin resistance and Alzheimer's disease. BMB Rep 2009;42:475-81
5. de la Monte SM, Longato L, Tong M, et al. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and nonalcoholic steatohepatitis. Curr Opin Investig Drugs 2009;10:1049-60
6. de la Monte SM, Tong M, Wands JR. Insulin resistance, cognitive impairment, and neurodegeneration: roles of nitrosamine exposure, diet, and lifestyles. In: de la Monte SM, editor. Alzheimer's disease pathogenesis-core concepts, shifting paradigms and therapeutic Targets. InTech, Rijeka, Croatia; 2011. p. 459-96
7. de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012;72:49-66
8. Derakhshan F, Toth C. Insulin and the brain. Curr Diabetes Rev 2013;9:102-16
9. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimer's Dis 2005;7:45-61 (Pubitemid 40387184)
10. Xu J, Yeon JE, Chang H, et al. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem 2003;278:26929-37 (Pubitemid 36876845)
11. Soscia SJ, Tong M, Xu XJ, et al. Chronic gestational exposure to ethanol causes insulin and IGF resistance and impairs acetylcholine homeostasis in the brain. Cell Mol Life Sci 2006;63:2039-56 (Pubitemid 44359744)
12. Benedict C, Hallschmid M, Schultes B, et al. Intranasal insulin to improve memory function in humans. Neuroendocrinology 2007;86:136-42 (Pubitemid 47494214)
13. Freiherr J, Hallschmid M, Frey WH II, et al. Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 2013;27:505-14
14. Henkin RI. Intranasal insulin: from nose to brain. Nutrition 2010;26:624-33
15. Suzuki Y, Takeda M. Expression of insulin-like growth factor family in the rat olfactory epithelium. Anat Embryol (Berl) 2002;205:401-5
16. Ferguson MW, Sharpe PM, Thomas BL, et al. Differential expression of insulinlike growth factors I and II (IGF I and II), mRNA, peptide and binding protein 1 during mouse palate development: comparison with TGF beta peptide distribution. J Anat 1992;181(Pt 2):219-38 (Pubitemid 23068814)
17. Lester-Coll N, Rivera EJ, Soscia SJ, et al. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimer's Dis 2006;9:13-33
18. Moroz N, Tong M, Longato L, et al. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J Alzheimer's Dis 2008;15:29-44
19. de la Monte SM, Wands JR. Insulin resistance and neurodegeneration: type 2 versus Type 3 diabetes mellitus. Emerg Drugs Targets AD 2009;1:235-54
20. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-38
21. Sun X, Yao H, Douglas RM, et al. Insulin/PI3K signaling protects dentate neurons from oxygen-glucose deprivation in organotypic slice cultures. J Neurochem 2010;112:377-88
22. McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur J Pharmacol 2010;630:158-62
23. Scherer T, Lehnert H, Hallschmid M. Brain insulin and leptin signaling in metabolic control: from animal research to clinical application. Endocrinol Metab Clin North Am 2013;42:109-25
24. Wada A, Yokoo H, Yanagita T, et al. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics. J Pharmacol Sci 2005;99:128-43 (Pubitemid 41524451)
25. Ketterer C, Tschritter O, Preissl H, et al. Insulin sensitivity of the human brain. Diabetes Res Clin Pract 2011;93(Suppl 1):S47-51
26. Schioth HB, Frey WH, Brooks SJ, et al. Insulin to treat Alzheimer's disease: just follow your nose? Expert Rev Clin Pharmacol 2012;5:17-20
27. Molina JA, Jimenez-Jimenez FJ, Vargas C, et al. Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. Acta Neurol Scand 2002;106:347-50 (Pubitemid 36020741)
28. Fujisawa Y, Sasaki K, Akiyama K. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 1991;30:1219-28
29. Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164-8
30. de la Monte SM. Triangulated malsignaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimer's Dis 2012;30:S231-49
31. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2012;9:35-66
32. de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed) 2012;4:1582-605
33. de la Monte SM. Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin resistance diseases. Panminerva Med 2012;54:171-8
34. Hoyer S, Muller D, Plaschke K. Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism. J Neural Transm Suppl 1994;44:259-68 (Pubitemid 24372903)
35. Hoyer S, Lannert H, Noldner M, et al. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J Neural Transm 1999;106:1171-88 (Pubitemid 30009214)
36. Schubert M, Brazil DP, Burks DJ, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003;23:7084-92 (Pubitemid 36975873)
37. Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004;101:3100-5 (Pubitemid 38327741)
38. de la Monte SM, Tong M, Bowling N, et al. si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder. Mol Brain 2011;4:13
39. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 2002;109:341-60 (Pubitemid 34251638)
40. Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J Clin Invest 2012;122:1339-53
41. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38
42. de la Monte SM, Tong M, Lester-Coll N, et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimer's Dis 2006;10:89-109 (Pubitemid 44401370)
43. Laron Z. Insulin and the brain. Arch Physiol Biochem 2009;115:112-16
44. Morris JK, Burns JM. Insulin: an emerging treatment for Alzheimer's disease dementia? Curr Neurol Neurosci Rep 2012;12:520-7
45. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes: evidence reviewed. J Diabetes Sci Tech 2008;2:1101-13
46. Jauch-Chara K, Friedrich A, Rezmer M, et al. Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes 2012;61:2261-8
47. Posey KA, Clegg DJ, Printz RL, et al. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 2009;296:E1003-12
48. Bohringer A, Schwabe L, Richter S, et al. Intranasal insulin attenuates the hypothalamic-pituitary-adrenal axis response to psychosocial stress. Psychoneuroendocrinology 2008;33:1394-400
49. Bale TL, Anderson KR, Roberts AJ, et al. Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 2003;144:2580-7 (Pubitemid 36629911)
50. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann NY Acad Sci 2006;1083:77-110 (Pubitemid 44955468)
51. Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore longitudinal study of aging. JAMA Neurol 2013;70(9):1167-72
52. Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med 2013;369:540-8
53. Baker LD, Cross DJ, Minoshima S, et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011;68:51-7
54. Dominguez RO, Marschoff ER, Gonzalez SE, et al. Type 2 diabetes and/ or its treatment leads to less cognitive impairment in Alzheimer's disease patients. Diabetes Res Clin Pract 2012;98:68-74
55. Henkin RI. Inhaled insulinintrapulmonary, intranasal, and other routes of administration: mechanisms of action. Nutrition 2010;26:33-9
56. Hanson LR, Frey WH II. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5
57. Benedict C, Frey WH II, Schioth HB, et al. Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 2011;46:112-15
58. Chapman CD, Frey WH II, Craft S, et al. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res 2013;30(10):2475-84
59. Messier C, Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 2005;12:311-28 (Pubitemid 43072007)
60. Reger MA, Watson GS, Frey WH II, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27:451-8 (Pubitemid 43185331)
61. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dosedependently modulates verbal memory and plasma amyloid-beta in memoryimpaired older adults. J Alzheimer's Dis 2008;13:323-31 (Pubitemid 352039034)
62. Ott V, Benedict C, Schultes B, et al. Intranasal administration of insulin to the brain impacts cognitive function and peripheral metabolism. Diabetes Obes Metab 2012;14:214-21
63. Shemesh E, Rudich A, Harman-Boehm I, et al. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012;97:366-76
64. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70:440-8
65. Schioth HB, Craft S, Brooks SJ, et al. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol 2012;46:4-10
66. Hallschmid M, Benedict C, Schultes B, et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept 2008;149:79-83
67. Ryan KK, Woods SC, Seeley RJ. Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity. Cell Metab 2012;15:137-49
68. Reagan LP. Insulin signaling effects on memory and mood. Curr Opin Pharmacol 2007;7:633-7 (Pubitemid 350177560)
69. Hallschmid M, Benedict C, Schultes B, et al. Intranasal insulin reduces body fat in men but not in women. Diabetes 2004;53:3024-9 (Pubitemid 39425932)
70. Guthoff M, Grichisch Y, Canova C, et al. Insulin modulates food-related activity in the central nervous system. J Clin Endocrinol Metab 2010;95:748-55
71. Guthoff M, Stingl KT, Tschritter O, et al. The insulin-mediated modulation of visually evoked magnetic fields is reduced in obese subjects. PLoS one 2011;6:e19482
72. Hallschmid M, Benedict C, Schultes B, et al. Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 2008;32:275-82 (Pubitemid 351271786)
73. Heni M, Kullmann S, Ketterer C, et al. Nasal insulin changes peripheral insulin sensitivity simultaneously with altered activity in homeostatic and rewardrelated human brain regions. Diabetologia 2012;55:1773-82
74. Benedict C, Kern W, Schultes B, et al. Differential sensitivity of men and women to anorexigenic and memoryimproving effects of intranasal insulin. J Clin Endocrinol Metab 2008;93:1339-44 (Pubitemid 351519730)
75. Krug R, Benedict C, Born J, et al. Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 2010;95:E468-72
76. Kullmann S, Frank S, Heni M, et al. Intranasal insulin modulates intrinsic reward and prefrontal circuitry of the human brain in lean women. Neuroendocrinology 2013;97:176-82
77. Francis GJ, Martinez JA, Liu WQ, et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008;131:3311-34
78. Bonifacio E, Achenbach P, Pan L, et al. Mucosal insulin vaccination for type 1 diabetes prevention. Exp Clin Endocrinol Diabetes 2008;116(Suppl 1):S26-9
79. Nanto-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372:1746-55
80. Vig PJ, Subramony SH, D'Souza DR, et al. Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Res Bull 2006;69:573-9
81. Liu XF, Fawcett JR, Hanson LR, et al. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc 2004;13:16-23 (Pubitemid 38419175)
82. Lin S, Fan LW, Rhodes PG, et al. Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 2009;217:361-70
83. Kooijman R, Sarre S, Michotte Y, et al. Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke 2009;40:e83-8
84. Patel MM, Goyal BR, Bhadada SV, et al. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009;23:35-58
85. Reger MA, Craft S. Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin. Drugs Today (Barc) 2006;42:729-39 (Pubitemid 46084772)
86. D'Souza R, Mutalik S, Venkatesh M, et al. Insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies. AAPS PharmSciTech 2005;6:E184-9 (Pubitemid 41631754)
87. Teijeiro-Osorio D, Remunan-Lopez C, Alonso MJ. New generation of hybrid poly/oligosaccharide nanoparticles as carriers for the nasal delivery of macromolecules. Biomacromolecules 2009;10:243-9
88. Sakuma S, Suita M, Masaoka Y, et al. Oligoarginine-linked polymers as a new class of penetration enhancers. J Control Release 2010;148:187-96
89. McInnes FJ, O'Mahony B, Lindsay B, et al. Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. Eur J Pharm Sci 2007;31:25-31 (Pubitemid 46601867)
90. Chung SW, Hil-lal TA, Byun Y. Strategies for non-invasive delivery of biologics. J Drug Target 2012;20:481-501
91. Illum L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J Pharm Sci 2007;96:473-83 (Pubitemid 46466073)
92. Arnold JJ, Fyrberg MD, Meezan E, et al. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-D-maltoside. J Pharm Sci 2010;99:1912-20
93. Duan X, Mao S. New strategies to improve the intranasal absorption of insulin. Drug Discov Today 2010;15:416-27
94. Stote R, Marbury T, Shi L, et al. Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Tech 2010;4:603-9
95. Stote R, Miller M, Marbury T, et al. Enhanced absorption of Nasulin, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. J Diabetes Sci Tech 2011;5:113-19
96. Krishnankutty RK, Mathew A, Sedimbi SK, et al. Alternative routes of insulin delivery. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009;34:933-48
97. Leary AC, Stote RM, Breedt HJ, et al. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. Diabetes Technol Ther 2005;7:124-30 (Pubitemid 40354582)
98. Strachan MW. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem Soc Trans 2005;33:1037-40 (Pubitemid 41659108)
99. Benedict C, Hallschmid M, Schmitz K, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2007;32:239-43 (Pubitemid 44967803)
100. Benedict C, Dodt C, Hallschmid M, et al. Immediate but not long-term intranasal administration of insulin raises blood pressure in human beings. Metabolism 2005;54:1356-61 (Pubitemid 41262594)
101. Hotta O, Taguma Y, Chiba S, et al. Possible relationship between hyperinsulinemia and glomerular hypertrophy in nephrosclerosis. Ren Fail 1996;18:271-8 (Pubitemid 26138725)
102. Luchsinger JA, Tang MX, Shea S, et al. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63:1187-92 (Pubitemid 39350015)
103. Fishel MA, Watson GS, Montine TJ, et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005;62:1539-44 (Pubitemid 41434558)
104. Neumann KF, Rojo L, Navarrete LP, et al. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res 2008;5:438-47
105. Roriz-Filho SJ, Sa-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta 2009;1792:432-43
106. Lahousse SA, Carter JJ, Xu XJ, et al. Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol 2006;7:41
107. Imfeld P, Bodmer M, Jick SS, et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a populationbased case-control study. J Am Geriatr Soc 2012;60:916-21
108. Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-8 (Pubitemid 46638661)
109. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006;6:246-54 (Pubitemid 44137951)
110. Roses AD, Saunders AM, Huang Y, et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 2007;7:10-28 (Pubitemid 46322076)
111. Escribano L, Simon AM, Gimeno E, et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010;35:1593-604
112. Escribano L, Simon AM, Perez-Mediavilla A, et al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 2009;379:406-10
113. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010;30:131-46
114. Tzimopoulou S, Cunningham VJ, Nichols TE, et al. A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimer's Dis 2010;22:1241-56
115. Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011;8:592-606
116. Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann Pharmacother 2011;45:1416-24
117. Galea E, Feinstein DL, Lacombe P. Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice. Diabetologia 2006;49:2153-61 (Pubitemid 44168484)